| Erin Laing Ohmann, MD | |
|
1250 Waters Place, Tower 2 9th Floor, Bronx, NY 10461 | |
| (929) 263-3992 | |
| (929) 263-3952 |
| Full Name | Erin Laing Ohmann |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Experience | 13 Years |
| Location | 1250 Waters Place, Bronx, New York |
| Accepts Medicare Assignments | May be. She may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548551781 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Montefiore Medical Center | Bronx, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Montefiore Medical Center | 3779496021 | 2003 |
News Archive
The UK based developer of next generation proton therapy technology, Advanced Oncotherapy plc, has selected RayStation as its treatment planning system for the first LIGHT system at the proton therapy facility under construction at Harley Street in central London.
Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.
Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.
At first, 13-year-old Christina Blumstein thought she had an ordinary headache. She and her parents were returning from a visit to Long Island in July 2014 when the pain struck. Was it a bout of carsickness? Too much screen time on her iPad? But a few hours later, back home in Old Bridge, New Jersey, her mother MaryAnn says, "Christina started screaming that somebody was stabbing her in the head with a knife." Soon afterward Christina was comatose and in an ambulance - and her life was in grave danger.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.
› Verified 4 days ago
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
The UK based developer of next generation proton therapy technology, Advanced Oncotherapy plc, has selected RayStation as its treatment planning system for the first LIGHT system at the proton therapy facility under construction at Harley Street in central London.
Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.
Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.
At first, 13-year-old Christina Blumstein thought she had an ordinary headache. She and her parents were returning from a visit to Long Island in July 2014 when the pain struck. Was it a bout of carsickness? Too much screen time on her iPad? But a few hours later, back home in Old Bridge, New Jersey, her mother MaryAnn says, "Christina started screaming that somebody was stabbing her in the head with a knife." Soon afterward Christina was comatose and in an ambulance - and her life was in grave danger.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Erin Laing Ohmann, MD 1250 Waters Place, Tower 1 Ph, Bronx, NY 10461 Ph: (347) 842-1719 | Erin Laing Ohmann, MD 1250 Waters Place, Tower 2 9th Floor, Bronx, NY 10461 Ph: (929) 263-3992 |
News Archive
The UK based developer of next generation proton therapy technology, Advanced Oncotherapy plc, has selected RayStation as its treatment planning system for the first LIGHT system at the proton therapy facility under construction at Harley Street in central London.
Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.
Houston Technology Center (HTC), announced today that client company Salient Pharmaceuticals received a $2 million commercialization award from the Texas Emerging Technology Fund (TETF) for the commercialization of their CASAD therapy, an all natural product used to prevent and treat some cancer therapy-induced side effects.
At first, 13-year-old Christina Blumstein thought she had an ordinary headache. She and her parents were returning from a visit to Long Island in July 2014 when the pain struck. Was it a bout of carsickness? Too much screen time on her iPad? But a few hours later, back home in Old Bridge, New Jersey, her mother MaryAnn says, "Christina started screaming that somebody was stabbing her in the head with a knife." Soon afterward Christina was comatose and in an ambulance - and her life was in grave danger.
Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today the dosing of the first subject in a Phase 2 study with an experimental oral parathyroid hormone analog for the treatment of osteoporosis in postmenopausal women.
› Verified 4 days ago
Dr. Eduardo Sin Enriquez, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 234 E 149th St, Bronx, NY 10451 Phone: 718-579-5710 | |
Dr. Azfar Uddin Shaikh, M.D Urology Medicare: Not Enrolled in Medicare Practice Location: 1400 Pelham Pkwy S, Bronx, NY 10461 Phone: 718-918-5000 Fax: 914-493-1679 | |
Raphael Novogrodsky, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 4238 Bronx Blvd, Bronx, NY 10466 Phone: 718-743-7090 | |
Dr. John Robert Carlucci, MD Urology Medicare: Medicare Enrolled Practice Location: 1650 Grand Concourse, Department Of Surgery, Bronx, NY 10457 Phone: 718-590-1800 | |
Dr. Jonathan Fleischmann, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2510 Westchester Ave, Suite A, Bronx, NY 10461 Phone: 718-517-3030 Fax: 718-517-3031 | |
Kara Watts, MD Urology Medicare: May Accept Medicare Assignments Practice Location: 111 E 210th St, 5th Floor, Dept. Of Urology, Bronx, NY 10467 Phone: 718-920-4531 | |
Dr. Nefertiti Childrey, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 234 E 149th St Ste 2a7, Bronx, NY 10451 Phone: 718-579-6672 |